Apligraf®

From Organogenesis, Inc.

Apligraf® is a living bi-layered therapy that is the only product with FDA approval for the treatment of both venous leg ulcers and diabetic foot ulcers. Apligraf is easy to incorporate into practice and has positive reimbursement in all settings. Apligraf has been extensively studied in multiple clinical trials and has been used to treat many thousands of patients.

Product Specs

Apligraf is indicated for the treatment of non-infected partial- and full-thickness venous leg ulcers with standard therapeutic compression (ulcers that have not adequately responded to at least 1 month of conventional therapy). Apligraf is also indicated for the treatment of full-thickness neuropathic diabetic foot ulcers when used with standard diabetic foot ulcer care (ulcers extending through the dermis but without tendon, muscle, capsule, or bone exposure, that have not adequately responded to at least 3 weeks of conventional therapy).

This product is listed in

• Biosynthetic dressings and skin substitutes